文献速递胸部肿瘤

卡马替尼联合那扎替尼治疗EGFR突变非小细胞肺癌患者

Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2024-06-22

这项1b/2期试验评估卡马替尼联合那扎替尼在晚期EGFR突变非小细胞肺癌中的疗效与安全性。2期试验中,RP2D为卡马替尼400 mg每日两次联合那扎替尼100 mg每日一次;2期共纳入144例,各组ORR分别为28.8%、33.3%、61.7%和42.9%。结论认为联合方案在EGFR-TKI耐药患者中显示出抗肿瘤活性,总体安全性可接受。

要点

  • RP2D为卡马替尼400 mg每日两次联合那扎替尼100 mg每日一次。
  • 2期组1、2、3、4的ORR分别为28.8%、33.3%、61.7%、42.9%。
  • 组1+1b期RP2D中,MET+、MET-、T790M+、T790M-的ORR分别为45.8%、26.2%、37.9%、32.4%。

核心结论

  • 卡马替尼联合那扎替尼在EGFR-TKI耐药、EGFR突变NSCLC患者中显示出抗肿瘤活性,总体安全性可接受。

研究设计与样本

  • 1b/2期试验,1b期纳入第一/二代EGFR-TKI进展后患者,卡马替尼200-400 mg每日两次联合那扎替尼50-150 mg每日一次剂量递增。
  • 确定MTD/RP2D后进入2期,按突变状态和既往治疗线数分组,2期共纳入144例。

主要发现

  • 2期组1(n=52)、组2(n=3)、组3(n=47)、组4(n=42)的ORR分别为28.8%、33.3%、61.7%、42.9%。
  • 组1+1b期RP2D中,MET+(n=24)、MET-(n=42)、T790M+(n=29)、T790M-(n=34)的ORR分别为45.8%、26.2%、37.9%、32.4%。
  • 最常见的任何级别治疗相关不良事件(≥25%;n=144)为外周水肿54.9%、恶心41.7%、腹泻34.0%、斑丘疹25.0%。

关键数值与推荐

  • RP2D为卡马替尼400 mg每日两次联合那扎替尼100 mg每日一次。
  • 2期主要终点为研究者按RECIST v1.1评估的ORR(组1-3)、安全性和耐受性(组4,随餐给药)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This phase 1b/2 trial evaluated the efficacy and safety of capmatinib plus nazartinib in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). METHODS: In phase 1b, patients with progression on first-/second-generation EGFR-TKIs received escalating doses of capmatinib 200-400 mg bid plus nazartinib 50-150 mg qd. Once the MTD/RP2D was declared, phase 2 commenced with patient enrollment into groups according to mutation status and prior lines of treatment: group 1 (fasted; EGFR-TKI resistant; 1-3 prior lines; EGFRL858R/ex19del; any T790M/MET); group 2 (fasted; EGFR-TKI naïve; 0-2 prior lines; de novo T790M+; any MET); group 3 (fasted; treatment-naïve; EGFRL858R/ex19del; T790M-; any MET); group 4 (with food; 0-2 prior lines; EGFRL858R/ex19del; any T790M/MET). Primary endpoints in phase 2 were investigator-assessed overall response rate (ORR) per RECIST v1.1 (groups 1-3), safety, and tolerability of the combination with food (group 4). Efficacy was assessed by T790M and MET status for a subgroup of patients. RESULTS: The RP2D was capmatinib 400 mg bid plus nazartinib 100 mg qd. In phase 2 (n = 144), the ORR was 28.8 %, 33.3 %, 61.7 %, and 42.9 % in groups 1 (n = 52), 2 (n = 3), 3 (n = 47), and 4 (n = 42), respectively. In group 1 +phase 1b RP2D, the ORR was 45.8 %, 26.2 %, 37.9 %, and 32.4 % in MET+ (n = 24), MET- (n = 42), T790M+ (n = 29), and T790M- (n = 34) patients. Most common any-grade treatment-related adverse events (≥25 %; n = 144) were peripheral edema (54.9 %), nausea (41.7 %), diarrhea (34.0 %), and maculopapular rash (25.0 %). CONCLUSION: Capmatinib plus nazartinib showed antitumor activity in patients with EGFR-TKI-resistant, EGFR-mutated NSCLC. The overall safety profile was acceptable. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT02335944.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Felip E, Metro G, Soo RA, et al. Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer. Eur J Cancer. 2024. PMID: 38986421. doi:10.1016/j.ejca.2024.114182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。